Savara(US:SVRA) Prnewswire·2025-10-09 12:45Core Points - The Gross Law Firm has issued a notice to shareholders of Savara Inc. (NASDAQ: SVRA) regarding a class action lawsuit related to misleading statements made by the company during a specified class period [1][2] - The allegations include that Savara's treatment, MOLBREEVI BLA, lacked sufficient information for FDA approval, which could lead to delays and the need for additional capital [1] - Shareholders are encouraged to register for the class action by November 7, 2025, to monitor the case's progress [2] Summary by Sections Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara made materially false and misleading statements regarding MOLBREEVI BLA [1] - Specific allegations include insufficient information about the treatment's chemistry and manufacturing, making FDA approval unlikely [1] - The delay in regulatory approval could necessitate additional capital raising for the company [1] Next Steps for Shareholders - Shareholders who purchased SVRA shares during the class period should register to participate in the class action [2] - Registration includes enrollment in a portfolio monitoring software for status updates on the case [2] - The deadline for seeking lead plaintiff status is November 7, 2025, with no cost to participate [2] About the Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3]